λÖãº
Ê×Ò³
>
²úÆ·ÖÐÐÄ
>
ScleraxisͬԴÎïB ELISA¼ì²âÊÔ¼ÁºÐ
> ÔÚÏßÁôÑÔ
ScleraxisͬԴÎïB ELISA¼ì²âÊÔ¼ÁºÐ
·µ»Ø²úÆ·ÏêÇé
ÁôÑÔÀàÐÍ
²É¹º×Éѯ
ÊÛºó×Éѯ
ÄúµÄÐÕÃû
µç»°
Email
µ¥Î»Ãû³Æ
ÁôÑÔÄÚÈÝ
ÎÒ¶ÔÄúµÄScleraxisͬԴÎïB ELISA¼ì²âÊÔ¼ÁºÐ²úÆ·¸ÐÐËȤ£¬Çë·¢¾ßÌåµÄÐÅÏ¢¼°±¨¼Û£¬Ð»Ð»£¡
IPµØÖ·
18.188.132.71
ÑéÖ¤Âë
¿´²»Çå³þ£¿µã»÷ͼƬ»»Ò»ÕÅ¡£
ͬƷÅƲúÆ·£º
¦Á2¾ÞÇòµ°°×(¦Á2-MG)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1171
)
Arylamine N-acetyltransferase 1(NAT1)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1713
)
¿ÉÌæÄþ(Cot)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1482
)
ϸ°ûÉ«ËØcÑõ»¯Ã¸ÑÇ»ù5B(COX5B)ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1114
)
CKB/Creatine kinase B-type ELISA¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1035
)
Ïà¹Ø²úÆ·£º
×é°·(HA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1173
)
5-ôÇÉ«°·(5-HT)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
876
)
¦Ã-°±»ù¶¡Ëá(gABA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1064
)
¦Â-ôǶ¡Ëá(bHB)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
1111
)
»¨ÉúËÄÏ©Ëá(AA)¼ì²âÊÔ¼ÁºÐ
¹Ø×¢(
870
)